Tvardi Therapeutics, Inc. (TVRD)
US — Healthcare Sector
Peers:
Automate Your Wheel Strategy on TVRD
With Tiblio's Option Bot, you can configure your own wheel strategy including TVRD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TVRD
- Rev/Share 0.8093
- Book/Share -0.8629
- PB -31.6892
- Debt/Equity 0.0
- CurrentRatio 32.4829
- ROIC -0.8115
- MktCap 255973811.0
- FreeCF/Share -3.7802
- PFCF -7.2379
- PE -5.6753
- Debt/Assets 0.0
- DivYield 0
- ROE 2.266
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | TVRD | Cantor Fitzgerald | -- | Overweight | -- | $52 | July 11, 2025 |
| Initiation | TVRD | Piper Sandler | -- | Overweight | -- | $78 | June 12, 2025 |
| Initiation | TVRD | Oppenheimer | -- | Outperform | -- | $65 | May 21, 2025 |
| Initiation | TVRD | BTIG Research | -- | Buy | -- | $55 | May 15, 2025 |
News
About Tvardi Therapeutics, Inc. (TVRD)
- IPO Date 2025-04-16
- Website https://tvarditherapeutics.com BioSpace +4
- Industry Biotechnology
- CEO Imran Alibhai
- Employees 17
Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Their lead candidate, TTI-101, is currently in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).